[Clinical evaluation of ofloxacin in the treatment of acute cystitis].
Ofloxacin (OFLX) was administered to 236 female patients with acute cystitis. Of them 164 patients who satisfied the criteria proposed by the UTI Committee, Japan were examined for the efficacy of the treatment, but all cases were included in the study of the side effects of the drug. In the 65 patients who received 300 mg (3 divided doses) of OFLX per day, the overall clinical efficacy was excellent in 66.2% and moderate in 33.8% of the patients. In the 99 patients who received 600 mg (3 divided doses) of OFLX per day, the overall clinical efficacy was excellent in 79% (P less than 0.076) and moderate in 18.2% of the patients. No failure of the treatment was observed in the two groups. Of 164 bacterial strains isolated from the urine of the patients, 132 strains were identified as E. coli. All bacterial strains were eradicated in the urinary specimens by the treatment. Subjective side effects were observed in 8 (3.4%) of the 236 patients. Gastrointestinal disturbance was complained by 6 patients. No drug-related aggravation in the laboratory test was observed except for one patient who showed mild leukopenia reduced from 3700/mm3 to 2200/mm3. These results showed that the oral administration of OFLX was excellent and satisfactory in the treatment for acute cystitis.
Sakashita
S
S
Kumagai
A
A
Kubota
M
M
Yamazaki
H
H
Nantani
M
M
Sakakibara
N
N
Tsubo
S
S
Togashi
M
M
Maru
A
A
Koyanagi
T
T
D000208:Acute Disease; D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D003556:Cystitis / Q000188:drug therapy* / Q000382:microbiology; D005260:Female; D006801:Humans; D008875:Middle Aged; D015242:Ofloxacin; D010078:Oxazines / Q000008:administration & dosage*
D010078:Oxazines; D015242:Ofloxacin